Olivia Cavlan

Partner at LifeArc

Speaker

Olivia joined LifeArc Ventures in 2025 and was previously Chief Corporate Development and Strategy Officer at the UK biotechnology company Alchemab Therapeutics, which she co-founded, with responsibility for global business development, partnerships, and corporate strategy. Before Alchemab, Olivia was an Investment Principal at SV Health Investors and a Partner at McKinsey & Company, where she was part of the leadership team in the Healthcare Private Equity and Pharmaceutical practices. At McKinsey, she co-led the global Real World Evidence practice and QuantumBlack’s biopharmaceutical offering, focusing on target discovery and clinical development. She has led global biopharma R&D transformation initiatives and developed clinical and commercial strategies for preclinical and clinical assets. Olivia is a Non-Executive Director of the UK BioIndustry Association and a member of the Investment Committee for Cancer Research UK’s (CRUK) Seed fund. She co-founded and sits on the Board of Sevenless Therapeutics, a company specialising in small molecule pain treatments. She holds an MBChB in Medicine and a BSc in Pharmacology from Bristol University.